A once-daily pill called orforglipron has emerged as a potential solution to one of the most vexing problems in the GLP-1 revolution: the rapid regain of weight after patients stop taking injectable treatments. Clinical data published in *Nature Medicine* and financed by Eli Lilly show that patients who switched to the oral compound after discontinuing injections maintained their reduced weight over a full year. The drug is already available in the United States and is expected to reach Britain soon. Viewed from Moscow, the commercial momentum is unmistakable: sales of GLP-1 agonists in Russia surged 3.5-fold in the first quarter of 2026 to 20.3 billion roubles, with tirzepatide alone accounting for over half that total. Yet the trajectory of these therapies is not confined to metabolic medicine.

Researchers in Hong Kong and Tokyo are independently advancing GLP-1 applications in stroke recovery, though through different biological pathways. Scientists at the Chinese University of Hong Kong have demonstrated that administering a GLP-1 injection before and after thrombectomy — a surgical procedure to remove blood clots from the brain — can improve neurological recovery in ischemic stroke patients by as much as 20 percent, particularly in those who missed the window for intravenous thrombolysis. From a Japanese perspective, a team at the Institute of Science Tokyo, led by Professor Takashi Shichita, has identified a drug candidate that suppresses a protein called insulin-like growth factor 1, which microglia secrete during rehabilitation. That protein currently limits motor-function recovery to roughly two months after a stroke. The new candidate aims to extend that window, offering a complementary approach to the Hong Kong group's focus on acute neuroprotection.

Beyond the brain, cardiologists are re-evaluating GLP-1 drugs as cardiovascular protectants independent of weight loss. Clinical evidence now shows that in high-risk patients — those with obesity, type 2 diabetes, or established heart disease — these therapies reduce the incidence of myocardial infarction and stroke. Meanwhile, a German research team at Helmholtz Munich has tested an experimental quintuple agonist, GLP-1-GIP-Lani, that combines the familiar appetite-regulating hormones with PPAR activity to improve insulin sensitivity, fat metabolism, and liver health. Described as a “Trojan horse” by lead investigator Timo D. Müller, the drug targets five receptor systems and could outperform existing treatments if later-stage trials succeed.

What unites these disparate advances is a recognition that GLP-1-based molecules are becoming platform technologies rather than simple weight-loss aids. The oral orforglipron addresses the adherence and cost barriers that have limited injectables, while the stroke and cardiovascular data expand the patient populations that might qualify for treatment. Regulators in London, Washington, and Tokyo will face rising pressure to approve these indications, but questions about long-term safety, pricing, and equitable access remain unresolved. For now, the clinical pipeline suggests that the GLP-1 story is only beginning to reveal its full scope.